梯瓦制药Teva Pharmaceutical Industries Limited (TEVA) 2012年年度报告「NYSE」.pdf

1、Table of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIES EXCHANGE ACT OF 1934OR xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended D

2、ecember 31,2012OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from to Commission File number:0-16174OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934Date of event requiring this shell com

3、pany report:TEVA PHARMACEUTICAL INDUSTRIES LIMITED(Exact name of Registrant as specified in its charter)Not Applicable(Translation of Registrants name into English)ISRAEL(Jurisdiction of incorporation or organization)5 Basel StreetP.O.Box 3190Petach Tikva 49131,Israel(Address of principal executive

4、offices)Eyal DeshehChief Financial OfficerTeva Pharmaceutical Industries Limited5 Basel StreetP.O.Box 3190Petach Tikva 49131,IsraelTel:972-3-914-8171Fax:972-3-914-8678(Name,telephone,e-mail and/or facsimile number and address of Company contact person)Securities registered or to be registered pursua

5、nt to Section 12(b)of the Act.Title of each class Name of each exchange on which registeredAmerican Depositary Shares,each representing one Ordinary Share New York Stock ExchangeSecurities registered or to be registered pursuant to Section 12(g)of the Act.None(Title of Class)Securities for which the

6、re is a reporting obligation pursuant to Section 15(d)of the Act.None(Title of Class)Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual report.943,619,967 Ordinary Shares696,251,654 American Deposita